TRT and low libido: what the testosterone research actually shows

What's this video probably claiming?

Based on the caption, hashtags, and the creator's known focus on TRT and hormone optimization through Haven Center in Tulsa, this video is almost certainly pitching testosterone replacement therapy as a primary solution for low libido and reduced sexual drive. Creators in this space typically frame low testosterone as the obvious culprit behind intimacy problems, position TRT as straightforward and safe, and encourage viewers to show the video to their partners, which functions as social proof and a soft referral mechanism. Dr. Babb operates in a clinical context, so the claims are likely more grounded than the average wellness influencer, but the framing almost always oversimplifies a genuinely complicated diagnostic picture. Low libido has dozens of contributing factors, and a 60-second TikTok is not going to cover the differential diagnosis with any real rigor.

What does the science actually show?

Testosterone does play a real role in sexual desire in both men and women, but the relationship is far messier than TRT content typically acknowledges. In men with confirmed hypogonadism, testosterone therapy does improve libido. The AUA 2018 guidelines and the landmark TRAVERSE trial (Lincoff et al., 2023, NEJM) confirmed cardiovascular safety in middle-aged and older men with hypogonadal symptoms, and earlier work like Isidori et al. (2005, Clinical Endocrinology) showed a statistically significant but modest improvement in sexual function scores with testosterone therapy in hypogonadal men. In women, the data is thinner and more contested. The APHRODITE trial (Davis et al., 2008, NEJM) showed transdermal testosterone at 300mcg per day improved satisfying sexual events in postmenopausal women, but the FDA has never approved a testosterone product specifically for women's sexual dysfunction, partly due to long-term safety concerns. The numbers show real effects, but effect sizes are moderate, not transformative.

Where does the social media noise diverge from clinical reality?

The biggest problem with TRT content targeting libido is selection bias in how results get presented. Creators show success stories. They don't show the patients whose low libido was driven by depression, relationship conflict, sleep apnea, medication side effects, or thyroid dysfunction, all of which are far more common causes than frank hypogonadism in many age groups. A 2021 review in Sexual Medicine Reviews (Rastrelli and Maggi) noted that psychological and relational factors account for a substantial portion of low libido cases that get referred for hormonal workup. Starting TRT without ruling those out is putting the cart before the horse. There's also a real issue with subclinical or borderline testosterone levels being treated aggressively. Many men in the 300-400 ng/dL range get offered TRT despite those levels not meeting traditional hypogonadism criteria, and the clinical benefit at that range is genuinely uncertain. Framing TRT as the obvious answer glosses over all of this.

What should you actually know?

If you or your partner are dealing with low libido, a hormonal evaluation is a reasonable starting point, but it's one piece of a larger workup. Total and free testosterone, SHBG, LH, FSH, prolactin, and thyroid panels are all relevant. A morning serum testosterone below 300 ng/dL on two separate measurements is the general threshold most guidelines use to consider TRT in men. In women, there is no validated threshold for testosterone treatment of sexual dysfunction. Beyond labs, a thorough medication review matters, SSRIs, beta blockers, hormonal contraceptives, and antihistamines all suppress libido at clinically meaningful rates. Relationship factors, sleep quality, and mental health should all be on the table before jumping to a prescription. TRT is a real intervention with real benefits for the right patient, but it is not a universal fix, and it carries real considerations including suppression of endogenous testosterone production, potential fertility effects, and hematocrit changes that require monitoring.